vs
BIODESIX INC（BDSX）与RBB Bancorp（RBB）财务数据对比。点击上方公司名可切换其他公司
RBB Bancorp的季度营收约是BIODESIX INC的1.1倍（$32.3M vs $28.8M），RBB Bancorp净利率更高（31.5% vs -13.8%，领先45.3%），BIODESIX INC同比增速更快（40.8% vs 12.6%），RBB Bancorp自由现金流更多（$42.6M vs $692.0K），过去两年BIODESIX INC的营收复合增速更高（39.3% vs 7.0%）
BIODESIX INC是一家专注于肿瘤与感染病领域的分子诊断企业，开发并商业化创新血液检测解决方案，主要服务北美地区的医疗机构、生物制药合作伙伴及患者，核心业务包括辅助临床决策的个性化医疗产品。
RBB银行控股公司是总部位于美国的金融控股集团，旗下核心主体为皇家商业银行，主要服务亚裔社群、中小微企业、不动产投资者及零售客户，提供商业信贷、储蓄存款、财富管理等多元金融服务，业务覆盖美国沿海核心都会区。
BDSX vs RBB — 直观对比
营收规模更大
RBB
是对方的1.1倍
$28.8M
营收增速更快
BDSX
高出28.2%
12.6%
净利率更高
RBB
高出45.3%
-13.8%
自由现金流更多
RBB
多$41.9M
$692.0K
两年增速更快
BDSX
近两年复合增速
7.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $28.8M | $32.3M |
| 净利润 | $-4.0M | $10.2M |
| 毛利率 | — | — |
| 营业利润率 | -6.8% | 39.5% |
| 净利率 | -13.8% | 31.5% |
| 营收同比 | 40.8% | 12.6% |
| 净利润同比 | 51.8% | 132.1% |
| 每股收益（稀释后） | $-3.35 | $0.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDSXRBB
| Q4 25 | $28.8M | $32.3M | ||
| Q3 25 | $21.8M | $32.6M | ||
| Q2 25 | $20.0M | $35.8M | ||
| Q1 25 | $18.0M | $28.5M | ||
| Q4 24 | $20.4M | $28.7M | ||
| Q3 24 | $18.2M | $30.3M | ||
| Q2 24 | $17.9M | $27.5M | ||
| Q1 24 | $14.8M | $28.2M |
净利润BDSXRBB
| Q4 25 | $-4.0M | $10.2M | ||
| Q3 25 | $-8.7M | $10.1M | ||
| Q2 25 | $-11.5M | $9.3M | ||
| Q1 25 | $-11.1M | $2.3M | ||
| Q4 24 | $-8.3M | $4.4M | ||
| Q3 24 | $-10.3M | $7.0M | ||
| Q2 24 | $-10.8M | $7.2M | ||
| Q1 24 | $-13.6M | $8.0M |
营业利润率BDSXRBB
| Q4 25 | -6.8% | 39.5% | ||
| Q3 25 | -32.4% | 40.7% | ||
| Q2 25 | -48.6% | 36.1% | ||
| Q1 25 | -50.9% | 11.2% | ||
| Q4 24 | -32.5% | 17.6% | ||
| Q3 24 | -47.3% | 31.6% | ||
| Q2 24 | -46.0% | 35.6% | ||
| Q1 24 | -74.4% | 39.9% |
净利率BDSXRBB
| Q4 25 | -13.8% | 31.5% | ||
| Q3 25 | -40.0% | 31.2% | ||
| Q2 25 | -57.3% | 26.1% | ||
| Q1 25 | -61.8% | 8.0% | ||
| Q4 24 | -40.4% | 15.3% | ||
| Q3 24 | -56.5% | 23.1% | ||
| Q2 24 | -60.3% | 26.4% | ||
| Q1 24 | -91.9% | 28.4% |
每股收益（稀释后）BDSXRBB
| Q4 25 | $-3.35 | $0.59 | ||
| Q3 25 | $-1.16 | $0.59 | ||
| Q2 25 | $-0.08 | $0.52 | ||
| Q1 25 | $-0.08 | $0.13 | ||
| Q4 24 | $-5.02 | $0.26 | ||
| Q3 24 | $-1.40 | $0.39 | ||
| Q2 24 | $-0.08 | $0.39 | ||
| Q1 24 | $-0.14 | $0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.0M | $212.3M |
| 总债务越低越好 | $50.0M | $119.9M |
| 股东权益账面价值 | $-2.5M | $523.4M |
| 总资产 | $87.5M | $4.2B |
| 负债/权益比越低杠杆越低 | — | 0.23× |
8季度趋势，按日历期对齐
现金及短期投资BDSXRBB
| Q4 25 | $19.0M | $212.3M | ||
| Q3 25 | $16.6M | $234.9M | ||
| Q2 25 | $20.7M | $191.9M | ||
| Q1 25 | $17.6M | $238.8M | ||
| Q4 24 | $26.2M | $257.7M | ||
| Q3 24 | $31.4M | $349.4M | ||
| Q2 24 | $42.2M | $252.8M | ||
| Q1 24 | $11.5M | — |
总债务BDSXRBB
| Q4 25 | $50.0M | $119.9M | ||
| Q3 25 | $50.0M | $119.8M | ||
| Q2 25 | $50.0M | $119.7M | ||
| Q1 25 | $40.0M | $119.6M | ||
| Q4 24 | $40.0M | $119.5M | ||
| Q3 24 | $40.0M | $119.4M | ||
| Q2 24 | $40.1M | $119.3M | ||
| Q1 24 | $40.1M | $119.2M |
股东权益BDSXRBB
| Q4 25 | $-2.5M | $523.4M | ||
| Q3 25 | $-1.7M | $514.3M | ||
| Q2 25 | $1.1M | $517.7M | ||
| Q1 25 | $11.1M | $510.3M | ||
| Q4 24 | $20.9M | $507.9M | ||
| Q3 24 | $27.9M | $509.7M | ||
| Q2 24 | $36.3M | $511.3M | ||
| Q1 24 | $-5.5M | $514.0M |
总资产BDSXRBB
| Q4 25 | $87.5M | $4.2B | ||
| Q3 25 | $88.7M | $4.2B | ||
| Q2 25 | $87.7M | $4.1B | ||
| Q1 25 | $86.2M | $4.0B | ||
| Q4 24 | $97.2M | $4.0B | ||
| Q3 24 | $102.7M | $4.0B | ||
| Q2 24 | $115.8M | $3.9B | ||
| Q1 24 | $87.2M | $3.9B |
负债/权益比BDSXRBB
| Q4 25 | — | 0.23× | ||
| Q3 25 | — | 0.23× | ||
| Q2 25 | 43.95× | 0.23× | ||
| Q1 25 | 3.62× | 0.23× | ||
| Q4 24 | 1.92× | 0.24× | ||
| Q3 24 | 1.44× | 0.23× | ||
| Q2 24 | 1.10× | 0.23× | ||
| Q1 24 | — | 0.23× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $778.0K | $43.4M |
| 自由现金流经营现金流 - 资本支出 | $692.0K | $42.6M |
| 自由现金流率自由现金流/营收 | 2.4% | 131.8% |
| 资本支出强度资本支出/营收 | 0.3% | 2.5% |
| 现金转化率经营现金流/净利润 | — | 4.26× |
| 过去12个月自由现金流最近4个季度 | $-23.5M | $73.5M |
8季度趋势，按日历期对齐
经营现金流BDSXRBB
| Q4 25 | $778.0K | $43.4M | ||
| Q3 25 | $-8.9M | $2.1M | ||
| Q2 25 | $-6.6M | $21.7M | ||
| Q1 25 | $-8.6M | $7.8M | ||
| Q4 24 | $-4.1M | $58.5M | ||
| Q3 24 | $-10.7M | $24.5M | ||
| Q2 24 | $-18.6M | $11.7M | ||
| Q1 24 | $-15.3M | $4.8M |
自由现金流BDSXRBB
| Q4 25 | $692.0K | $42.6M | ||
| Q3 25 | $-8.9M | $1.8M | ||
| Q2 25 | $-6.6M | $21.6M | ||
| Q1 25 | $-8.7M | $7.6M | ||
| Q4 24 | $-4.9M | $57.7M | ||
| Q3 24 | $-10.9M | $24.2M | ||
| Q2 24 | $-20.5M | $11.5M | ||
| Q1 24 | $-15.5M | $4.7M |
自由现金流率BDSXRBB
| Q4 25 | 2.4% | 131.8% | ||
| Q3 25 | -41.0% | 5.4% | ||
| Q2 25 | -33.1% | 60.2% | ||
| Q1 25 | -48.3% | 26.7% | ||
| Q4 24 | -24.2% | 201.0% | ||
| Q3 24 | -60.1% | 80.0% | ||
| Q2 24 | -114.3% | 42.0% | ||
| Q1 24 | -104.9% | 16.6% |
资本支出强度BDSXRBB
| Q4 25 | 0.3% | 2.5% | ||
| Q3 25 | 0.2% | 1.1% | ||
| Q2 25 | 0.3% | 0.3% | ||
| Q1 25 | 0.4% | 0.6% | ||
| Q4 24 | 4.1% | 2.7% | ||
| Q3 24 | 1.3% | 0.8% | ||
| Q2 24 | 10.7% | 0.5% | ||
| Q1 24 | 1.6% | 0.5% |
现金转化率BDSXRBB
| Q4 25 | — | 4.26× | ||
| Q3 25 | — | 0.21× | ||
| Q2 25 | — | 2.32× | ||
| Q1 25 | — | 3.39× | ||
| Q4 24 | — | 13.34× | ||
| Q3 24 | — | 3.50× | ||
| Q2 24 | — | 1.61× | ||
| Q1 24 | — | 0.60× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDSX
| Diagnostic Tests | $25.1M | 87% |
| Development Services | $3.6M | 13% |
RBB
暂无分部数据
